PERITONEAL CANCER

This study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep cancer from growing back in women whose ovarian, peritoneal, or fallopian tube cancer has returned but responded well to platinum-based chemotherapy. The goal is to see…

This study is for women whose ovarian cancer has returned but responded well to a second round of platinum chemotherapy. It tests if adding a newer, targeted drug (mirvetuximab soravtansine) to a standard maintenance drug (bevacizumab) can keep the cancer controlled longer and pr…

This early-stage study is testing if adding aspirin to standard chemotherapy helps the body's immune system better fight ovarian, fallopian tube, or peritoneal cancer. It will involve 100 adults who are scheduled for chemotherapy before surgery. Researchers will measure changes i…

This large international study is testing which treatment strategy works better to control advanced ovarian, fallopian tube, or peritoneal cancer after initial chemotherapy. It compares taking the drug niraparib alone versus taking niraparib plus another drug called bevacizumab. …

This study is testing whether a blood conservation technique called acute normovolemic hemodilution (ANH) can reduce the need for donor blood transfusions during ovarian cancer surgery. Researchers will randomly assign 86 patients undergoing surgery for advanced ovarian cancer to…

This study is testing whether virtual reality (VR) can help reduce pain and improve quality of life for people with gastrointestinal cancers. Researchers will compare three approaches: VR that teaches pain management skills, VR designed to distract from pain, and a basic VR contr…

This study aims to identify what factors are linked to how long patients live after being diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer. It will observe 371 patients over several years, collecting detailed health information and quality of life surveys. Th…